SKK
TCRT icon

Shepherd Kaplan Krochuk’s Alaunos Therapeutics TCRT Stock Holding History

Shepherd Kaplan Krochuk’s Portfolio TCRT Stock Details TCRT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q2 		– Sell
-323
Closed -$222K – 619
2014
Q1 		$222K Buy
+323
New +$216K 0.03% 432

Other funds holding TCRT

TS
Third Security Radford, Virginia $241M AUM 45.43% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
MP
MSD Partners New York $82.3M AUM 15.13% 1-Year Est. Return
EWM
Essex Woodlands Management The Woodlands, Texas $251M AUM 13.72% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
BGA
Belmont Global Advisors Dallas, Texas $106M AUM 2.89% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Shepherd Kaplan Krochuk's TCRT Position: Q2 2014 in Review

Shepherd Kaplan Krochuk sold out of Alaunos Therapeutics (TCRT) in Q2 2014, closing a stake of 323 shares — an estimated $222K sold.

Shepherd Kaplan Krochuk first reported a position in TCRT in Q1 2014 and held it in 1 quarter. The position peaked at $222K in Q1 2014. 92 funds tracked by Wall St. Rank hold TCRT as of Q2 2014.

  • Shepherd Kaplan Krochuk reported no remaining Alaunos Therapeutics position as of Q2 2014 after selling out during the quarter.
  • Shepherd Kaplan Krochuk sold 323 Alaunos Therapeutics shares in Q2 2014, an estimated $222K.
  • Shepherd Kaplan Krochuk first reported a position in Alaunos Therapeutics in Q1 2014 and held it in 1 quarter.
  • Shepherd Kaplan Krochuk's Alaunos Therapeutics position peaked at $222K in Q1 2014.
  • 92 funds tracked by Wall St. Rank held Alaunos Therapeutics as of Q2 2014.

Based on Shepherd Kaplan Krochuk's 13F filing for Q2 2014, filed 14 Aug 2014.